BridgeBio raises $1 billion in convertible preferred equity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
July 1, 2026 7:30 AM EDT- Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100% premium to Companys 30-day VWAP)
- The financing significantly strengthens the Companys balance sheet, enabling it to efficiently allocate capital across its highest return opportunities
- The financing comes at a pivotal moment for the Company, as Attruby® continues to grow into a multi-billion-dollar blockbuster drug, and as BridgeBio prepares for three additional potential blockbuster U.S. product launches over the next 12 months across... More
